Testing effectiveness (Phase 2)Study completedNCT04133948
What this trial is testing
Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma
Who this might be right for
Malignant Melanoma Stage III
The Netherlands Cancer Institute 44